证券代码：688136 证券简称：科兴制药 公告编号：2024-064 科兴生物制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金理财产品结算账户的开立情况 科兴生物制药股份有限公司（以下简称"公司"）为满足部分暂时闲置募集 资金现金管理的需要，在招商银行股份有限公司深圳宝安支行等开立了募集资金 理财产品结算账户，具体内容详见公司分别于2021年2月5日、2021年9月3日、2024 年6与7日在上海证券交易所网站（www.see.com.cn）披露的《关于开立理财产品 专用结算账户的公告》（公告编号：2021-008、2021-038、2024-042）。 二、募集资金理财产品结算账户的注销情况 截至本公告披 露 日 ， 公 司 在 招 商 银 行 深 圳 宝 安 支 行 账 户 （ 账 号 ： 531902250710119）购买的理财产品均已全部到期赎回，且不再使用该账户。根 据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》及 《上海证券交易所科创板上市公司自律监管指引 ...

（一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 证券代码：688136 证券简称：科兴制药 公告编号：2024-060 科兴生物制药股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第十六次会 议于 2024 年 8 月 19 日以现场结合通讯的方式召开。会议通知已于 2024 年 8 月 13 日发出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 经各位监事认真审议，会议形成了如下决议： 公司监事会认为：公司严格按照各项法律、法规、规章的要求规范运作，公 司《2024 年半年度报告及其摘要》真实、公允地反映了公司 2024 年半年度的财 务状况和经营成果。在作出本决议之前，未发现参与 2024 年半年度报告编制和 审议的人员存在违反保密规定的行为。因此，同意《公司 ...

科兴生物制药股份有限公司 证券代码：688136 证券简称：科兴制药 公告编号：2024-062 关于终止部分日常关联交易协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●是否需要提交股东大会审议：否 ●对上市公司的影响：公司根据目前生产经营的具体安排，与相关交易对方 经过审慎协商达成一致并经公司董事会审议通过后，终止上述日常关联交易协议。 上述日常关联交易协议的终止符合相关法律法规，不存在损害公司及股东利益情 形，对公司正常生产经营活动无影响。 三、关联交易标的基本情况 此次终止关联交易协议涉及的云升天纪物业位于广州市黄埔区光谱中路 11 号云升科学园 1#楼 2 层 04+06 单位，面积 1650 平方米，五年租金总额约 482.03 万元，物业管理费五年总额约为 79.20 万元。 四、本次交易终止事项对公司的影响 公司控股子安合动保原计划承租上述标的，扩大日常经营场地，用于建设生 物安全防护二级（P2）实验室，开展载体疫苗研发过程中的毒种库制备等与病原 菌相关的研发实验。根据公司发展战 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-061 科兴生物制药股份有限公司 2024 年半年度募集资金存放及实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》和《上 海证券交易所科创板股票上市规则》等有关规定，科兴生物制药股份有限公司（以 下简称"本公司"或"公司"）董事会对 2024 年半年度募集资金存放和实际使 用情况专项报告说明如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655 号）同意，公司首次公开发 行人民币普通股 4,967.5300 万股，每股面值人民币 1.00 元，每股发行价为人民 币 22.33 元，本次发行募集资金总额为 1,109,249,449.00 元，扣除保荐承销等 发行费用 114,608,529.84 元 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-063 科兴生物制药股份有限公司 关于对山东证监局行政监管措施决定书的整改报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）及相关人 员于2024年8月1日收到中国证券监督管理委员会山东监管局（以下简称"山东证 监局"）下发的《行政监管措施决定书》（〔2024〕76号、77号，以下统称"《决 定书》"），要求公司对《决定书》中指出的问题进行整改。相关内容详见公司 于2024年8月3日披露在上海证券交易所网站（www.sse.com.cn）的《关于公司及 相关人员收到中国证券监督管理委员会山东监管局<行政监管措施决定书>的公 告》（公告编号：2024-058）。 收到《决定书》后，公司对《决定书》中涉及的问题进行了全面梳理和针对 性地分析研讨，同时根据相关法律法规、规范性文件及公司各项管理制度的规定 和要求，结合公司实际情况，按照《决定书》中的要求逐项梳理并认真落实整改 措施。具体如下： 一、公 ...

Financial Performance - The company's operating revenue for the first half of 2024 reached ¥759,894,679.84, representing a 17.09% increase compared to the same period last year[12]. - The net profit attributable to shareholders of the listed company was ¥11,877,328.48, a significant recovery from a loss of ¥47,561,505.48 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥21,530,307.28, compared to a loss of ¥71,740,894.74 in the same period last year[12]. - The net cash flow from operating activities was -¥34,029,158.20, an improvement from -¥87,139,193.83 in the previous year[12]. - The total assets at the end of the reporting period were ¥3,098,824,269.38, reflecting a 2.23% increase from the previous year[12]. - The net assets attributable to shareholders of the listed company decreased by 1.22% to ¥1,606,230,170.26 compared to the end of the previous year[12]. - The company achieved a net profit attributable to shareholders, marking a significant increase compared to the same period last year, primarily due to a 17.09% increase in revenue from core products including Yipuding, Sairuojin, and Baitexi[13]. - The basic earnings per share for the reporting period was not applicable, with diluted earnings per share also not applicable, reflecting a shift from a loss of 0.24 yuan per share in the previous year[13]. - The weighted average return on equity after deducting non-recurring gains and losses was 1.33%, a recovery from -4.01% in the same period last year[13]. - The company reported a revenue of 12,352.7 billion RMB in the first half of 2024, a year-on-year decline of 0.9%[22]. Research and Development - Research and development expenses accounted for 11.52% of operating income, a decrease of 18.49 percentage points compared to the previous year[13]. - The company has established a comprehensive R&D system with capabilities spanning drug discovery to industrialization, focusing on recombinant protein drugs and antibody drugs[21]. - The company has 12 innovative drug projects in focus, with multiple projects entering the process development stage[29]. - The company has achieved significant milestones in R&D, including breakthroughs in high-concentration formulations and eukaryotic expression systems[23]. - The company’s antibody drug development platform has successfully supported the development of multiple projects, including GB10 and GB18, with promising lead compounds[23]. - The company has invested CNY 87.54 million in R&D during the reporting period, focusing on antiviral, oncology, immune, and degenerative diseases[41]. - The first self-developed Class 1 innovative drug, Fc fusion protein-long-acting growth hormone, has entered Phase I clinical trials, and the inhalation solution of human interferon α1b is in Phase III trials[39]. - The company is focusing on the development of new therapies for chronic diseases, including multiple myeloma and breast cancer, to enhance its product portfolio[20]. Market Position and Product Development - The company has established strategic partnerships with several pharmaceutical companies to commercialize key drugs, enhancing its market presence in over 70 countries[17]. - The market share of Sairuojin® in the domestic short-acting interferon market remains the highest, while Yipuding ranks second in the domestic erythropoietin market[17]. - The company is actively expanding its oncology product line, including the introduction of Paclitaxel for various cancer treatments, indicating a focus on growth in the oncology sector[20]. - The company has submitted a listing application for its Palbociclib capsules in the U.S., reflecting its international market ambitions[20]. - The company’s biosimilar Infliximab has been recognized for its efficacy and safety, being the first of its kind launched in China, which strengthens its competitive edge[20]. - The company has developed a patented formulation of Erythropoietin that reduces blood-borne contamination and allergic reactions, making it one of only two manufacturers in China for a specific indication[18]. - The company has obtained registration for its traditional Chinese medicine product in Hong Kong, indicating its market expansion efforts[20]. - The company introduced 13 new products, focusing on oncology, autoimmune diseases, and metabolic diseases, to support its overseas commercialization strategy[35]. Financial Management and Investments - The company has established a marketing distribution network covering nearly 22,700 terminals in the domestic market[21]. - The company has established a marketing network covering approximately 7,000 hospitals in China, enhancing its market position and brand advantage[32]. - The company has invested a total of CNY 200,000,000.00 in a private equity fund aimed at expanding potential cooperation opportunities in the health industry[53]. - The company has recognized a cumulative profit impact of CNY -13,940,667.35 from its private equity investments[54]. - The total amount of raised funds is CNY 110,924.94 million, with a net amount after issuance costs of CNY 99,464.09 million[110]. - The company has utilized CNY 25,000 million of idle raised funds for cash management, with a cash management balance of CNY 7,000 million at the end of the reporting period[115]. - The company has received regulatory warnings for non-compliance in cash management of raised funds but has rectified the situation by redeeming non-principal guaranteed financial products[116]. Environmental and Social Responsibility - The company has invested 670,500 CNY in environmental protection during the reporting period[60]. - The company operates wastewater treatment facilities with a total design capacity of 1,100 m³/d, all running normally[61]. - The company has established an emergency response plan for environmental incidents, with a validity period of three years[65]. - The company has implemented an online monitoring system for wastewater and conducts regular third-party testing for emissions[66]. - The company has confirmed compliance with pollution discharge standards, with no exceedances reported[60]. - The company has received environmental impact assessment approvals for new projects, including the industrialization of polyethylene glycol-stimulated human granulocyte colony-stimulating factor injection[64]. - The company actively responds to the national "carbon neutrality" strategy by adopting low-carbon energy-saving measures and utilizing new technologies to reduce greenhouse gas emissions[70]. Corporate Governance and Compliance - The company has commitments from major shareholders and management regarding share restrictions, effective from March 31, 2020, until December 13, 2025, ensuring compliance with lock-up periods[71]. - The company has not reported any mergers or acquisitions during the reporting period[69][70][71][72]. - The company will publicly explain any failure to fulfill commitments made during the IPO and apologize to shareholders and public investors[90]. - The company will ensure that any stock incentive plans are tied to the execution of measures to compensate for diluted returns[82]. - The company has maintained a good credit status, with no significant debts that are overdue or unfulfilled[102]. - The company received administrative regulatory measures from the China Securities Regulatory Commission and the Shanghai Stock Exchange in August 2024, indicating compliance issues that require rectification[101]. Shareholder Information - The total number of ordinary shareholders as of the reporting period is 9,456[119]. - The company reported a total of 131,778,347 shares outstanding, with significant holdings from major shareholders including 1,764,125 shares held by the chairman, Deng Xueqin[120]. - Deng Xueqin increased his shareholding by 762,710 shares during the reporting period, reflecting a strong confidence in the company's future[121]. - The company granted a total of 780,000 new restricted stocks to key management personnel, indicating a commitment to incentivize and retain talent[122]. - The total number of shares held by the top ten shareholders includes a significant portion of 1,880,572 shares held by a repurchase account, representing 0.94% of the total shares[120]. Asset and Liability Management - The total liabilities as of June 30, 2024, were CNY 1,486.24 million, compared to CNY 1,400.30 million at the end of 2023, reflecting an increase of approximately 6.1%[127]. - The total assets reached CNY 3,098.82 million, up from CNY 3,031.09 million, indicating a growth of about 2.2%[127]. - The company's cash and cash equivalents decreased to CNY 439.76 million from CNY 568.80 million, a decline of approximately 22.7%[125]. - The total equity attributable to shareholders decreased to CNY 1,606.23 million from CNY 1,626.02 million, a decline of about 1.2%[127]. - The inventory level decreased to CNY 155.87 million from CNY 191.36 million, a reduction of approximately 18.5%[125].

证券代码：688136 证券简称：科兴制药 公告编号：2024-059 经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 根据《中华人民共和国证券法》、中国证监会《公开发行证券的公司信息披 露内容与格式准则第 3 号——半年度报告的内容与格式》、《上海证券交易所科 创板股票上市规则》等有关规定,董事会全体成员对公司《2024 年半年度报告》 及《2024 年半年度报告摘要》进行审阅。公司 2024 年半年度报告未经会计师事 务所审计；经本次董事会审议通过后，同意对外报送公司《2024 年半年度报告》 及《2024 年半年度报告摘要》。 科兴生物制药股份有限公司 第二届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 科兴生物制药股份有限公司（以下简称"公司"）第二届董事会第十七次会议 于 2024 年 8 月 19 日在深圳市南山区创益科技大厦 B 栋 19 楼会议室以现场结合 通讯的方式召开。本次会议通知于 202 ...

上 海 证 券 交 易 所 关于对科兴生物制药股份有限公司及有关责任 人予以监管警示的决定 上证科创公监函〔2024〕0036 号 当事人： 科兴生物制药股份有限公司，A 股证券简称：科兴制药，A 股证券代码：688136； 邓学勤，科兴生物制药股份有限公司时任董事长； 赵彦轻，科兴生物制药股份有限公司时任总经理； 王小琴，科兴生物制药股份有限公司时任财务总监兼董事 会秘书。 根据中国证券监督管理委员会山东监管局《关于对科兴生物 制药股份有限公司采取责令改正、出具警示函措施的决定》 （〔2024〕76 号）和《关于对邓学勤、赵彦轻、王小琴采取出具 警示函措施的决定》（〔2024〕77 号）（以下合称《行政监管措施》） 查明的事实，科兴生物制药股份有限公司（以下简称科兴制药或 公司）存在下列违规行为。 二是未保持自愿信息披露的持续性。2022 年，公司自愿披 露了人干扰素α2b 泡腾胶囊临床试验申请获得受理、收到药物 临床试验批准通知书等公告。但是，该项目于 2024 年 1 月终止， 公司未及时披露相关终止情况，仅在 2023 年年报中予以披露。 三是使用募集资金进行现金管理不规范。2023 年以来，公 司存 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-057 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司 关于注销部分募集资金专户的公告 科兴生物制药股份有限公司(以下简称"公司")近日办理完成部分募集资金 专项账户的注销手续，现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655号）同意，公司首次公开发 行人民币普通股4,967.5300万股，每股面值人民币1.00元，每股发行价为人民币 22.33元，本次发行募集资金总额为1,109,249,449.00元，扣除保荐承销等发行 费用114,608,529.84元，募集资金净额为994,640,919.16元。上述募集资金已全 部到位，经大华会计师事务所（特殊普通合伙）验资，并于2020年12月7日出具 大华验字[2020]000752号《验资报告》验证确认。 上述募集资金到账后，公司依照规定对上述募集资金进行专户存储 ...

证券代码：688136 证券简称：科兴制药 公告编号：2024-058 科兴生物制药股份有限公司 关于公司及相关人员收到中国证券监督管理委员会山东监管局 《行政监管措施决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）及相关人员于近日分别收 到中国证券监督管理委员会山东监管局（以下简称"山东监管局"）下达的《行 政监管措施决定书》（〔2024〕76号、77号），现就主要内容公告如下： 一、《行政监管措施决定书》内容 "科兴生物制药股份有限公司、邓学勤、赵彦轻、王小琴： 前期，我局对你公司开展了现场检查。经查，你公司存在以下问题: 一、2023年年度业绩预告信息披露不准确。2024年1月31日，你公司披露《2023 年年度业绩预告》，预计2023年度实现归属于母公司所有者的净利润为-11,000 万元到-8,500万元，扣除非经常性损益后的净利润为-12,000万元到-9,500万元。 2024年2月24日，你公司披露《2023年年度业绩预告更正公告》，更正后预计20 ...